Latest Hydrazines Stories
NESS ZIONA, Israel, April 15, 2013 /PRNewswire/ -- NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its Phase IIa clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula under development for continuous sub-cutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels in Parkinson's disease. In previous phase I...
NESS ZIONA, Israel, November 20, 2012 /PRNewswire/ -- NeuroDerm, Ltd. announced today that enrollment of healthy subjects is ongoing in its Phase I clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula administered continuously via a subcutaneous delivery patch device. It is designed to provide steady levodopa blood levels and enhanced bioavailability of oral levodopa for the...
A new delivery method for levodopa/carbidopa, a common dual-drug Parkinson’s disease (PD) regimen, significantly improved the duration of the drugs’ effectiveness in people with advanced PD, according to research led by Dr. C. Warren Olanow at Mount Sinai School of Medicine. New York, NY (PRWEB) June 21, 2012 A new delivery method for levodopa/carbidopa, a common dual-drug Parkinson’s disease (PD) regimen, significantly improved the duration of the drugs’ effectiveness in people...
A levodopa-carbidopa intestinal gel (LCIG) works better than standard oral levodopa-carbidopa in reducing "off" time in patients with advanced Parkinson's disease. That's according to results of the phase three randomized, double-blind clinical trial of LCIG, to be presented as part of the Emerging Science program (formerly known as Late-Breaking Science) at the American Academy of Neurology's 64th Annual Meeting in New Orleans April 21 to April 28, 2012. "Off" time occurs when Parkinson's...
NEW ORLEANS, April 17, 2012 /PRNewswire-USNewswire/ -- A levodopa-carbidopa intestinal gel (LCIG) works better than standard oral levodopa-carbidopa in reducing "off" time in patients with advanced Parkinson's disease. That's according to results of the phase three randomized, double-blind clinical trial of LCIG, to be presented as part of the Emerging Science program (formerly known as Late-Breaking Science) at the American Academy of Neurology's 64th Annual Meeting in New...
ABBOTT PARK, Ill., April 17, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel (LCIG). The study showed that patients treated with LCIG for 12 weeks reported clinically meaningful and statistically significant improvements in "off" time compared to levodopa-carbidopa immediate release (IR) tablets, without increasing...
WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while levodopa remains the gold standard for Parkinson's disease treatment, physicians say they will increasingly use other agents to delay the need for levodopa. According to the new report entitled Treatment Algorithms in Parkinson's Disease, 46 percent of surveyed neurologists say it is "very likely" or "likely" they will...
SANTA ANA, Calif., July 28 /PRNewswire/ -- Alar Corporation is proud to announce the launch of its brand new website, http://www.alarcorporation.com.The new site provides users with a comprehensive overview of the company and features a compelling series of homepage videos and an interactive Risk Assessment Tool that guides users through a short list of questions to learn whether their company is at risk for workplace dysfunction such as theft, drugs, violence, turnover, or unknowingly...
